The U.S. Food and Drug Administration (FDA) has given its nod to tralokinumab-ldrm (Adbry, Leo Pharma) 300mg single-dose autoinjector for adults with moderate to severe atopic dermatitis (AD).
Tralokinumab-ldrmis is a high-affinity fully human monoclonal antibody developed to bind to and inhibit the interleukin (IL)-13 cytokine.
The new autoinjector is another option for adult patients in addition to the pre-filled syringe administration that is currently available. Prior to the introduction of the autoinjector, tralokinumab was only available in a 1mL pre-filled syringe. With the new 2mL autoinjector, adult patients now have a more convenient option with half the number of required injections compared to the 1mL pre-filled syringe.
In the U.S., Adbry is available in a single-use pre-filled syringe (150mg/1mL) as well as a single-use autoinjector (300mg/2mL). Adbry received approval from the U.S. For patients who prefer the pre-filled syringe, this option will continue to be available in the U.S.
